A phase II trial of ifosfamide, methotrexate, etoposide, and prednisolone (IMEP) for previously untreated stage I, II extranodal natural killer/T-cell lymphoma, nasal type (NTCL): A multicenter study of the Korean Cancer Study Group.

Tae Min Kim,Dong-Wan Kim,Yoon-Koo Kang,Goon-Jae Cho,Hong Suk Song,Hyo Jung Kim,Byung Soo Kim,Jong Seok Lee,Hawk Kim,Sung Hyun Yang,Young Jin Yuh,Sung Hwa Bae,Kyung Hee Lee,Yoon-Kyung Jeon,Chul Woo Kim,Dae Seog Heo

A phase II trial of ifosfamide, methotrexate, etoposide, and prednisolone (IMEP) for previously untreated stage I, II extranodal natural killer/T-cell lymphoma, nasal type (NTCL): A multicenter study of the Korean Cancer Study Group.

2017

Tae Min Kim
Dong-Wan Kim
Yoon-Koo Kang
Goon-Jae Cho
Hong Suk Song
Hyo Jung Kim
Byung Soo Kim
Jong Seok Lee
Hawk Kim
Sung Hyun Yang
Young Jin Yuh
Sung Hwa Bae
Kyung Hee Lee
Yoon-Kyung Jeon
Chul Woo Kim
Dae Seog Heo

8521 Background: Combination chemotherapy of IMEP was active as a first-line as well as a second-line treatment for NTCL in a retrospective analysis. Thus, we conducted a prospective, multicenter, ...

Keywords:

Pathology
Cancer
Prednisolone
Ifosfamide
Lymphoma
Methotrexate
Etoposide
Oncology
Internal medicine
Natural killer T cell
Chemotherapy
Medicine
Gastroenterology
combination chemotherapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations